Novartis announces positive results from phase III study of fingolimod in children & adolescents with MS
Novartis has announced positive topline results from the phase III PARADIGMS study, investigating the safety and efficacy of oral oncedaily fingolimod in children and adolescents (ages 10 to 17) with multiple06-09-2017